Iovance Biotherapeutics, Inc.

DB:2LB Stock Report

Market Cap: €2.2b

Iovance Biotherapeutics Management

Management criteria checks 3/4

Iovance Biotherapeutics' CEO is Frederick Vogt, appointed in Jul 2017, has a tenure of 7.5 years. total yearly compensation is $4.79M, comprised of 14.4% salary and 85.6% bonuses, including company stock and options. directly owns 0.069% of the company’s shares, worth €1.52M. The average tenure of the management team and the board of directors is 3.8 years and 7.6 years respectively.

Key information

Frederick Vogt

Chief executive officer

US$4.8m

Total compensation

CEO salary percentage14.4%
CEO tenure7.5yrs
CEO ownership0.07%
Management average tenure3.8yrs
Board average tenure7.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Frederick Vogt's remuneration changed compared to Iovance Biotherapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$410m

Jun 30 2024n/an/a

-US$440m

Mar 31 2024n/an/a

-US$450m

Dec 31 2023US$5mUS$692k

-US$444m

Sep 30 2023n/an/a

-US$433m

Jun 30 2023n/an/a

-US$419m

Mar 31 2023n/an/a

-US$412m

Dec 31 2022US$5mUS$650k

-US$396m

Sep 30 2022n/an/a

-US$390m

Jun 30 2022n/an/a

-US$376m

Mar 31 2022n/an/a

-US$358m

Dec 31 2021US$8mUS$471k

-US$342m

Sep 30 2021n/an/a

-US$311m

Jun 30 2021n/an/a

-US$284m

Mar 31 2021n/an/a

-US$265m

Dec 31 2020US$3mUS$418k

-US$260m

Sep 30 2020n/an/a

-US$255m

Jun 30 2020n/an/a

-US$246m

Mar 31 2020n/an/a

-US$230m

Dec 31 2019US$2mUS$398k

-US$198m

Sep 30 2019n/an/a

-US$167m

Jun 30 2019n/an/a

-US$151m

Mar 31 2019n/an/a

-US$134m

Dec 31 2018US$514kUS$375k

-US$124m

Compensation vs Market: Frederick's total compensation ($USD4.79M) is above average for companies of similar size in the German market ($USD1.50M).

Compensation vs Earnings: Frederick's compensation has been consistent with company performance over the past year.

CEO

Frederick Vogt (50 yo)

7.5yrs

Tenure

US$4,794,680

Compensation

Dr. Frederick G. Vogt, PhD, Esq., JD, serves as an Interim CEO & President at Iovance Biotherapeutics, Inc. since June 19, 2021 and is its Director since June 11, 2024. He has been the General Counsel at I...

Leadership Team

NamePositionTenureCompensationOwnership
Frederick Vogt
Interim CEO7.5yrsUS$4.79m0.069%
€ 1.5m
Jean-Marc Bellemin
CFO, Principal Accounting Officer & Treasurer4.1yrsUS$1.71m0.0096%
€ 211.8k
Igor Bilinsky
Chief Operating Officer3.8yrsUS$1.59m0.019%
€ 415.2k
Friedrich Graf Finckenstein
Chief Medical Officer5.5yrsUS$1.77m0.021%
€ 452.1k
Sara Pellegrino
Vice President of Investor Relations & Public Relationsno datano datano data
Tracy Winton
Executive Vice President of Human Resources2.8yrsno datano data
Howard Johnson
Chief Business Officer5.8yrsno datano data
Raj Puri
Chief Regulatory Officer2.8yrsno data0.051%
€ 1.1m
Brian Shew
Senior VP & Head of Digital and Information Technology2.8yrsno datano data
Kevin Smyth
Executive Vice President of Quality4yrsno datano data
Hequn Yin
Senior Vice President of Research2.8yrsno datano data
Brian Gastman
Executive Vice President of Medical Affairs1.5yrsno datano data

3.8yrs

Average Tenure

54.5yo

Average Age

Experienced Management: 2LB's management team is considered experienced (3.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Frederick Vogt
Interim CEOless than a yearUS$4.79m0.069%
€ 1.5m
Mario Sznol
Member of Scientific Advisory Boardno datano datano data
Wayne Rothbaum
Independent Director8.6yrsUS$240.00k9.21%
€ 202.5m
Michael Weiser
Independent Director6.8yrsUS$744.99k0.046%
€ 1.0m
Jeffrey Weber
Member of Scientific Advisory Boardno datano datano data
Patrick Hwu
Member of Scientific Advisory Boardno datano datano data
Ryan Maynard
Independent Director9.9yrsUS$489.99k0.0025%
€ 54.1k
Iain Dukes
Independent Chairman of the Board8.4yrsUS$933.48k0.018%
€ 389.7k
James Mule
Member of Scientific Advisory Boardno datano datano data
Athena Countouriotis
Independent Director5.6yrsUS$489.99k0%
€ 0
Cassian Yee
Member of Scientific Advisory Boardno datano datano data
Daniel Powell
Member of Scientific Advisory Boardno datano datano data

7.6yrs

Average Tenure

58.5yo

Average Age

Experienced Board: 2LB's board of directors are considered experienced (7.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 12:31
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Iovance Biotherapeutics, Inc. is covered by 24 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Madhu KumarBaird
Peter LawsonBarclays